Ashley Graham calls GLP-1 trend ‘a smack in the face’ to body positivity

Model argues that inclusivity gains remain despite growing popularity of weight-loss drugs

Ashley Graham has spoken out about the rising use of GLP-1 weight-loss medications, describing the trend as a setback for the body positivity movement she has championed throughout her career.

In a recent interview, Graham addressed the growing visibility of drugs used for weight management, which have become increasingly common in both Hollywood and wider public discourse. She suggested that their popularity has contributed to a renewed focus on thinness within fashion and entertainment, at a time when she believes the industry had been moving towards broader acceptance of diverse body types.

Graham characterised the shift as emotionally frustrating for many who have worked to promote body acceptance. She noted that the cultural emphasis on inclusivity had created space for a wider range of representation, but argued that the current direction feels like a reversal in tone rather than a complete undoing of progress.

GLP-1 medications, originally developed for medical conditions such as type 2 diabetes, have gained attention for their weight-loss effects by influencing appetite and metabolism. Their increased use among celebrities and public figures has intensified debate around body image, health messaging and the pressures placed on women in particular.

Despite her criticism of the trend, Graham emphasised that she does not believe the progress made in body positivity has been erased. She pointed to the continued presence of plus-size models, creators and public figures across media platforms, suggesting that representation remains visible and active even as beauty standards fluctuate.

Her comments also reflected a broader perspective on the fashion industry’s tendency to shift with cultural and commercial trends. According to Graham, these cycles are not new, and while certain ideals may gain prominence at different times, they do not fully eliminate other forms of representation.

Beyond her criticism, she reaffirmed her ongoing commitment to advocating for inclusivity, particularly in fashion and clothing design. Graham has long been involved in campaigns and collections aimed at expanding size diversity, and she continues to promote confidence across a wide range of body types.

Public reaction to her remarks has been mixed. Some have agreed with her concerns, arguing that the renewed focus on weight loss could undermine years of advocacy work. Others have suggested that individuals should have autonomy over their health choices without cultural judgement, framing the debate as more complex than a single narrative.

The discussion highlights an ongoing tension between medical innovation, personal choice and cultural messaging around appearance. As GLP-1 medications become more widely discussed, conversations around body image and representation are likely to continue evolving within both the fashion industry and wider society.

For Graham, the focus remains on sustaining visibility and confidence for women of all sizes, regardless of shifting trends in beauty standards.